Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.925 million to finance ongoing activities, particularly the clinical development of the AB8939 program [1][3]. Use of Proceeds - The net proceeds from the private placement will be utilized to support the clinical development of the AB8939 program and strengthen the company's cash position to meet financing needs for 2025 and beyond [3]. Private Placement Details - The private placement involved the issuance of 1,645,302 new ordinary shares, each with an attached share warrant (BSA), without preferential subscription rights [4][5]. - The issue price of one ABSA is EUR 1.17, reflecting a 24.36% discount to the volume-weighted average price (VWAP) of AB Science shares over the three trading days prior to the pricing [6][7]. Shareholder Impact - Post-placement, the new shares will represent approximately 2.47% of the company's share capital on a non-diluted basis before the placement and 2.41% after [5]. - Existing shareholders who do not participate in the private placement will experience a dilution of their shareholding [12][22]. Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on July 10, 2025, and will be assimilated to existing shares [13]. Lock-up Commitments - The company has agreed to a 45-day lock-up period for the investors and a 90-day lock-up for its directors and officers following the settlement and delivery of the private placement [17].

Core Viewpoint - AB Science has reached an agreement in principle with its financial creditors to postpone the repayment of its bank debt by 24 months, contingent upon the postponement of a loan repayment with the EIB by at least 12 months [2][7]. Group 1: Loan Repayment Terms - The total amount of bank debt to be postponed is approximately 3.7 million euros, with the agreement conditional on a 12-month delay for a 12 million euro loan from the EIB, originally due in January and December 2028 [2][4]. - The restructuring terms include state-guaranteed loans (PGE) with a balance of 3.5 million euros [3]. - A freeze on principal repayments is set from January 1, 2025, to December 31, 2026, with amortization resuming on January 1, 2027 [8]. Group 2: Financial Strategy - Savings from the postponed repayments will be invested in research and development [7]. - The EIB loan is structured in two tranches of 6 million euros each, with specific maturity dates in 2028 [4]. - An innovation loan with a balance of 0.2 million euros will also have a freeze on principal repayments from January 1, 2025, to September 30, 2025, with amortization resuming on October 1, 2025 [8]. Group 3: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5][6]. - The company's lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various disease areas [6].

Core Viewpoint - New peer-reviewed data supports masitinib's potential as a treatment for sporadic Alzheimer's disease through cognitive enhancement and neuroprotection [1][5][6] Group 1: Clinical Evidence - A new study from independent researchers indicates that masitinib improves cognitive functions in a mouse model of sporadic Alzheimer's disease, showing enhancements in memory, learning, and anxiety-like behaviors [3][4] - The study demonstrated that masitinib reduced toxic brain proteins, alleviated synaptic dysfunction, and suppressed microglial activation, which is linked to inflammation in Alzheimer's disease [4][5] - Results from a phase 2B/3 study (AB09004) showed that masitinib treatment significantly reduced cognitive impairment in patients with mild Alzheimer's disease, with a notable improvement in the mild impairment subgroup [8][9] Group 2: Regulatory and Development Status - The FDA and key EU countries have authorized a phase 3 clinical study (AB21004) to evaluate masitinib as a disease-modifying therapy for Alzheimer's disease [10][11] - The phase 3 study aims to confirm previous findings from the phase 2B/3 study regarding masitinib's efficacy in slowing cognitive deterioration and improving daily living activities [12] Group 3: Intellectual Property - AB Science has filed a patent application for masitinib's use in treating Alzheimer's disease, which, if granted, will provide protection until 2041 [13]

Company Overview - AB Science S.A. is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) [5] - The company is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [5] - AB Science focuses on diseases with high unmet medical needs, including oncology, neurological diseases, inflammatory diseases, and viral diseases [5] Recent Capital Increase - AB Science announced a capital increase of €1.8 million, which was settled and delivered on May 23, 2025 [1] - This capital increase was subscribed by a limited number of investors and is expected to strengthen the company's cash position [2] Product Development - Masitinib is a novel oral tyrosine kinase inhibitor being developed to target mast cells and macrophages, with potential applications in oncology, inflammatory diseases, and central nervous system diseases [3] - AB8939 is a new synthetic microtubule-destabilizing drug candidate that shows broad anticancer activity and may overcome drug resistance associated with standard chemotherapies [4]

Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.8 million to finance ongoing activities, particularly focusing on the clinical development of the AB8939 program [1][3]. Group 1: Private Placement Details - The private placement involved the issuance of 1,538,463 new ordinary shares, each with one share warrant attached, without preferential subscription rights [4]. - The issue price of one ABSA was set at EUR 1.17, reflecting a 24.8% discount to the volume-weighted average price over the three trading days prior [6][7]. - The total share capital post-placement will be EUR 661,764.30, comprising 59,368,757 ordinary shares, with potential increases if all BSAs are exercised [11]. Group 2: Use of Proceeds - The net proceeds from the private placement will primarily be allocated to the clinical development of the AB8939 program [3]. Group 3: Shareholder Impact - The issuance of ABSAs will result in a dilution of existing shareholders' stakes, with specific percentages outlined for major shareholders before and after the placement [12][14]. - The theoretical value of each BSA is estimated at EUR 0.4053, based on a volatility of 34.355% [9]. Group 4: Trading and Listing - The new shares are expected to be admitted to trading on Euronext Paris on May 22, 2025, and will be assimilated to existing shares [16]. - The BSAs are anticipated to be listed on Euronext Growth Paris by May 26, 2025 [10]. Group 5: Company Overview - AB Science specializes in the research, development, and commercialization of protein kinase inhibitors, targeting diseases with high unmet medical needs [25]. - The lead compound, masitinib, is being developed for various medical applications, including oncology and inflammatory diseases [25][23].

Core Insights - Masitinib demonstrates neuroprotective effects by lowering serum neurofilament light chain (NfL), a key biomarker for neurodegenerative disorders such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease [1][4][6] Group 1: Research Findings - The study published in PLOS One shows that masitinib can significantly reduce serum NfL levels, indicating its potential neuroprotective effects [1][3] - At Day 8, masitinib treatment reduced NfL levels by 43% at a dosage of 50 mg/kg/day and by 60% at 100 mg/kg/day, demonstrating a dose-dependent response [5][11] - Absolute serum NfL concentrations were approximately 25% lower in both masitinib treatment groups compared to the EAE control group at Day 8, with further reductions observed at Day 15 [5][6] Group 2: Mechanism of Action - Masitinib targets the innate neuroimmune system, specifically mast cells and microglia, which are implicated in the pathophysiology of neurodegenerative diseases [4][7] - The drug has shown clinical benefits in previous trials for progressive multiple sclerosis, ALS, and mild-to-moderate Alzheimer's disease, reinforcing its therapeutic promise [4][6] Group 3: Functional Performance - Masitinib treatment improved grip strength in EAE mouse models, with treated mice recovering to baseline levels by Day 15, indicating a protective effect on motor function [11] - Both treatment groups exhibited significantly less relative deterioration in grip strength compared to the EAE control group (p < 0.001) [11]

Financial and Corporate Situation - AB Science reported an operating deficit of €6.1 million as of December 31, 2024, a decrease of 55% compared to €13.4 million in 2023 [6][26] - The cash position stood at €8.0 million as of December 31, 2024 [6] - Operating income increased by 10% to €1.072 million in 2024 from €0.970 million in 2023 [27] - Operating expenses decreased by 50%, amounting to €7.244 million less than in 2023 [27][28] Clinical Development - AB Science provided updates on the AB8939 microtubule program, which targets relapsed/refractory acute myeloid leukaemia (AML) [3][4] - The Phase 1 study of AB8939 included 28 patients, assessing the maximum tolerated dose after 3 consecutive days of treatment, with a second stage nearing completion for 14 consecutive days [4][5] - AB8939 showed a 50% response rate against the MECOM gene rearrangement, which is associated with poor prognosis in AML [7][8] Masitinib Platform - Positive results were reported from the Phase 2 study of masitinib in COVID-19, with an odds ratio of 2.4 in favor of the treatment arm after 15 days [16][18] - The European Medicines Agency (EMA) issued a negative opinion for the conditional marketing authorization of masitinib in ALS [19] - A new confirmatory study for masitinib in ALS will be launched, targeting the best responders [21] Intellectual Property Developments - AB Science secured intellectual property rights for AB8939 in AML until 2036 and potentially until 2044 for specific chromosomal abnormalities [8] - New patents were granted for masitinib in the treatment of severe systemic mastocytosis, sickle cell disease, and other indications, extending protection until 2041 or 2042 [23][25][24] Capital Increase and Financial Strategy - A capital increase of €5 million was announced through the issuance of 5,368,725 new ordinary shares [31][34] - The proceeds from the capital increase will support AB Science's activities over the next twelve months [36] - The company has engaged in a Term Capital Increase Program (PACT) with Alpha Blue Ocean, which has provided additional funding [37] Market Position and Analyst Coverage - AB Science has received coverage initiation from DNA Finance and In Extenso Finance, with strong buy opinions indicating a compelling investment opportunity in the biotech sector [41][42]

Core Insights - AB Science announced new data from its phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS), which will be presented at the ENCALS annual meeting in June 2025, indicating masitinib's potential as a disease modifier [1][2] - The clinical benefit of masitinib is particularly pronounced in a subgroup of ALS patients prior to complete loss of function, supporting the rationale for a phase 3 confirmatory study [2] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3][4] - The company's lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various fields including oncology and neurological diseases [4] Clinical Findings - New analyses show that masitinib reduces serum neurofilament light chain (NfL) levels, suggesting a decrease in neuronal damage and supporting its disease-modifying potential in ALS [1][2] - Subgroup analyses indicate significant treatment effects in ALS patients before complete loss of function, with notable improvements in clinical endpoints and a +12-month survival benefit [2]

Company Announcement - AB Science SA has postponed the publication of its 2024 annual financial report from April 30, 2025, to May 9, 2025, to allow auditors to complete their work [1][2] Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3] - The company's lead compound, masitinib, is registered for veterinary medicine and is being developed for human medicine in areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases [4] Additional Information - AB Science is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [4] - Further information can be found on the company's website [5]